Rodman & Renshaw Maintains Market Perform on MannKind

Rodman & Renshaw is out with its report today on MannKind MNKD, maintaining Market Perform. In its report, Rodman & Renshaw writes, "With the clinical picture coming into view and the funding to support the two Phase 3 trials unspecified, we reiterate our Market Perform rating on Mannkind. We believe the clinical trial data that the company has presented has been impressive and the market opportunity for this Afrezza and the Dreamboat inhaler is much larger than the current valuation suggests." At the time of posting, shares of MNKD were trading at $2.78, up 2.58% from Thursday's close.